Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Mizuho

Mizuho assumed coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a research report sent to investors on Tuesday, MarketBeat reports. The brokerage issued an outperform rating and a $97.00 price target on the stock.

Other analysts have also issued reports about the stock. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective for the company. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a report on Wednesday, January 28th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Finally, Raymond James Financial assumed coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $54.63.

Maze Therapeutics Stock Up 13.3%

NASDAQ:MAZE opened at $51.06 on Tuesday. The stock has a fifty day simple moving average of $44.22 and a 200 day simple moving average of $35.12. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of -2.44 and a beta of 4.47. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $51.36.

Insiders Place Their Bets

In other news, CMO Harold Bernstein sold 15,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $46.02, for a total value of $690,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $596,908.60. This represents a 27.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 200,000 shares of company stock worth $8,254,792.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics in the fourth quarter worth $39,000. Ameritas Investment Partners Inc. increased its stake in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics during the fourth quarter worth $43,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.